Advertisement

Topics

Outlook Therapeutics initiated with an Outperform rating, $12 price target at Oppenheimer

07:41 EDT 17 May 2019 | Proactive Investors

Shares in the biopharma doubled after Oppenheimer analyst Leland Gershell saw promise in the company’s ONS-5010 eye medicine

Original Article: Outlook Therapeutics initiated with an Outperform rating, $12 price target at Oppenheimer

NEXT ARTICLE

More From BioPortfolio on "Outlook Therapeutics initiated with an Outperform rating, $12 price target at Oppenheimer"

Advertisement
Quick Search
Advertisement
Advertisement